01:42 , May 4, 2016 |  BC Extra  |  Financial News

MVM closes fourth fund at $233M

MVM Life Science Partners closed its fourth fund, MVM IV, at $233 million. The firm said it will invest $15-$30 million per company in healthcare companies of all stages in the U.S. and Europe. MVM...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Oral salmon calcitonin regulatory update

FDA accepted for review an NDA from Tarsa for once-daily Tbria salmon calcitonin delayed release tablets to treat postmenopausal osteoporosis in women >5 years postmenopause when alternative treatments are not suitable. The PDUFA date is...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

Tarsa Therapeutics financial update

Tarsa Therapeutics Inc. , Philadelphia, Pa.   Business: Musculoskeletal   Date announced: 2014-08-13   Note: Tarsa secured a $10 million senior credit facility from Oxford Finance and Square 1 Bank.  ...
08:00 , Dec 19, 2013 |  BC Innovations  |  Cover Story

Oral nanoparticles

Researchers from Brigham and Women's Hospital and the Massachusetts Institute of Technology have developed targeted nanoparticles that could enable the oral delivery of biologics such as insulin. 1 The clinical translation of the approach will...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Oral salmon calcitonin: Phase II data

The double-blind, U.S. Phase II TAR01-201 trial in 129 postmenopausal women with low bone mass at an increased risk of fracture showed that once-daily 200 mg oral Ostora met the primary endpoint of superiority to...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Unigene musculoskeletal news

Unigene said in its 2Q12 earnings that it will need to obtain "significant" funding to continue operations, address its debt and restructure its balance sheet. The company also noted that it was "unlikely" that Victory...
07:00 , Apr 30, 2012 |  BioCentury  |  Finance

Foreseeing liquidity

Foreseeing liquidity Foresite Capital has made five investments since its launch last summer, one of which became liquid about a week ago using the Form 10 pathway, the firm's founder and CEO, Jim Tananbaum, told...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Tarsa Therapeutics board of directors update

Tarsa Therapeutics Inc. , Philadelphia, Pa.   Business: Musculoskeletal   Appointed: James Tananbaum, CEO of Foresite Capital  ...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Financial News

Tarsa Therapeutics completes venture financing

Tarsa Therapeutics Inc. , Philadelphia, Pa.   Business: Musculoskeletal   Date completed: 3/16/12   Type: Venture financing   Raised: $28 million   Investors: Foresite Capital; Novo A/S; MVM Life Science Partners; Quaker Partners  ...